Skip to content

US · EVH · MEDICAL - HEALTHCARE INFORMATION SERVICES

Evolent Health, Inc. (EVH) intrinsic value and stock valuation

$3.90as of 2026-11-21 · Mkt cap 346.44M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Evolent Health, Inc. DCF and intrinsic value

InvestorsCraft values EVH with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from EVH’s statements →

Evolent Health, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Healthcare Information Services Arlington, VA 22209 evolent.com

How the business is doing

Fiscal 2012–2025, USD

Revenue
$1.88B+15.2% 5y CAGRd
20122025
Net income
-$-534.51M
20122025
Free cash flow
$4.75M
20122025
Total equity
$415.2M-7.7% 5y CAGRd
20122025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2012–2025, USD
20252024202320222021
Revenue$1.88B$2.55B$1.96B$1.35B$908M
Operating income-$-4.43M-$-40.48M-$-71.21M$3.64M-$-42.41M
Net income-$-534.51M-$-61.62M-$-113.04M-$-19.16M-$-37.6M
EPSd-$-4.68M-$-537.32K-$-1.02M-$-204.48K-$-436.85K
Operating cash flow$38.8M$18.8M$142.6M-$-11.55M$38.8M
Capital expenditure-$-34.09M-$-24.89M-$-28.75M-$-38.36M-$-24.98M
Free cash flow$4.75M-$-6.13M$113.8M-$-49.91M$13.8M
Total assets$1.9B$2.54B$2.68B$1.82B$1.42B
Total debt$989.7M$713.7M$644.8M$476.1M$280.5M
Net debt$837.8M$609.5M$452M$287.9M$14.2M
Total equity$415.2M$1B$1.07B$859.4M$693.6M
Cash and short-term investments$151.9M$163.5M$192.8M$188.2M$266.3M
Income statement
20252024202320222021
Revenue$1.88B$2.55B$1.96B$1.35B$908M
Cost of revenue$1.59B$2.19B$1.5B$1.04B$657.6M
Gross profit$284M$367.4M$460.5M$316.6M$250.4M
Research and development expenses$0.00$0.00$0.00$27M$0.00
Selling, general and administrative expenses$288.5M$263.1M$358.1M$269.3M$219.5M
Other expenses$0.00$144.8M$173.6M$16.7M$73.3M
Operating expenses$288.5M$407.8M$531.7M$312.9M$292.8M
Cost and expenses$1.88B$2.6B$2.04B$1.35B$950.4M
Interest income$4.19M$5.54M$5.26M$1.37M$410K
Interest expense$57.5M$24.7M$54.2M$15.6M$25.4M
Depreciation and amortization$115.9M$123.2M$123.4M$90.3M$60M
Ebitda-$-361.31M$84.9M-$-24.79M$43.8M$55.7M
Operating income-$-4.43M-$-40.48M-$-71.21M$3.64M-$-42.41M
Total other income/expenses, net-$-530.2M-$-22.55M-$-131.19M-$-65.72M$12.6M
Income before tax-$-534.64M-$-63.04M-$-202.41M-$-62.08M-$-29.8M
Income tax expense-$-130K-$-1.41M-$-89.36M-$-43.38M$480K
Net income-$-534.51M-$-61.62M-$-113.04M-$-19.16M-$-37.6M
Weighted average shares outstanding$114.2M$114.7M$111.3M$93.7M$86.1M
Weighted average diluted shares outstanding$114.2M$114.7M$111.3M$93.7M$86.1M
Balance sheet
20252024202320222021
Cash and short-term investments$151.9M$163.5M$192.8M$188.2M$266.3M
Net receivables$323.4M$414.7M$446.8M$254.7M$130.6M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$506.4M$607.1M$683.7M$478.1M$524M
Property, plant and equipment, net$85.2M$79.3M$90.2M$136.9M$131.6M
Goodwill and intangible assets$1.28B$1.82B$1.87B$1.17B$706.1M
Long-term investments$8.97M$8.59M$4.89M$4.47M$5.46M
Total non-current assets$1.39B$1.94B$2B$1.34B$895.5M
Total assets$1.9B$2.54B$2.68B$1.82B$1.42B
Accounts payable$59.8M$96M$48.3M$57.2M$96.1M
Short-term debt$15.3M$198.2M$9.74M$7.12M$7.07M
Deferred revenue$1.2M$2.51M$5.98M$5.76M$11.9M
Total current liabilities$385.3M$715.5M$674.2M$433.4M$445.5M
Long-term debt$974.4M$515.5M$635.1M$469M$273.4M
Deferred revenue, non-current$110K$0.00$0.00$0.00$0.00
Total non-current liabilities$1.1B$827.7M$938.4M$524.4M$280.3M
Capital lease obligations$19.2M$51.7M$47.8M$63.1M$64.8M
Total liabilities$1.48B$1.54B$1.61B$957.9M$725.8M
Common stock$1.18M$1.17M$1.15M$1.01M$910K
Retained earnings-$-1.32B-$-780.82M-$-719.19M-$-606.15M-$-626.78M
Accumulated other comprehensive income (loss)-$-2.62M-$-1.75M-$-1.26M-$-1.18M-$-360K
Total equity$415.2M$1B$1.07B$859.4M$693.6M
Total investments$8.97M$67.9M$4.89M$4.47M$5.46M
Total debt$989.7M$713.7M$644.8M$476.1M$280.5M
Net debt$837.8M$609.5M$452M$287.9M$14.2M
Cash flow statement
20252024202320222021
Net income-$-579.4M-$-61.62M-$-113.04M-$-19.16M-$-37.6M
Depreciation and amortization$122.6M$125.6M$123.4M$67.2M$60M
Stock-based compensation$39.7M$39.8M$40.5M$34M$16.7M
Change in working capital-$-57.38M-$-116.56M$21.9M-$-104.44M-$-22.49M
Accounts receivable$73.7M$32.1M-$-164.69M-$-102.98M-$-24.76M
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$6.64M$4.25M-$-6.72M$13.2M$7.25M
Net cash provided by operating activities$38.8M$18.8M$142.6M-$-11.55M$38.8M
Investments in property, plant and equipment-$-34.09M-$-24.89M-$-28.75M-$-38.36M-$-24.98M
Acquisitions, net-$-57.44M-$-30.73M$870K$5.55M$14.2M
Net cash used for investing activities-$-230K-$-62.93M-$-415.54M-$-259.12M-$-15.79M
Common stock issued$0.00$3.46M$180.5M$4.45M$13.3M
Common stock repurchased-$-40M$0.00$0.00$0.00$0.00
Dividends paid-$-11.13M-$-20.09M-$-18.79M-$-14.88M-$-1.3M
Net cash used for financing activities-$-35.92M-$-560K$281.3M$131.5M-$-29.55M
Net change in cash$14.5M-$-44.96M$8.3M-$-139.78M-$-6.64M
Cash at end of period$178M$178.5M$223.5M$215.2M$354.9M
Operating cash flow$38.8M$18.8M$142.6M-$-11.55M$38.8M
Capital expenditure-$-34.09M-$-24.89M-$-28.75M-$-38.36M-$-24.98M
Free cash flow$4.75M-$-6.13M$113.8M-$-49.91M$13.8M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Evolent Health, Inc.

        Evolent Health, Inc., a prominent healthcare firm, operates through its subsidiary, Evolent Health LLC, to furnish clinical and administrative solutions to both healthcare payers and providers across the United States. Its operations are divided into two principal segments: Evolent Health Services and Clinical Solutions. The Evolent Health Services division delivers an integrated platform encompassing both administrative and clinical functions, specifically designed for health plan management and the oversight of population health. This includes essential financial and administrative support, such as managing health plan operations, risk assessment, robust analytics and reporting, and strategic leadership. A cornerstone of this segment is "Identifi," its proprietary technology, which intelligently aggregates and analyzes data, streamlines care workflows, and actively engages patients, all with the aim of achieving patient-centered and cost-effective population health outcomes. Conversely, the Clinical Solutions segment specializes in offering sophisticated care management services for various stakeholders involved in specialty care delivery. These services are crucial for organizations transitioning from traditional fee-for-service models to value-based care, accommodating their unique stage of development and prevailing market dynamics, particularly in the fields of oncology and cardiology. The overarching objective of this segment is a holistic improvement in the total cost of care. Founded in 2011, Evolent Health, Inc. maintains its corporate headquarters in Arlington, Virginia.

        CEO
        Seth Barrie Blackley
        Employees
        4.2K
        Beta
        0.77

        Explore

        Frequently asked questions

        What is the intrinsic value of Evolent Health, Inc. (EVH)?

        Evolent Health, Inc. (EVH) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is EVH undervalued?

        EVH trades at a price of $3.90 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.